1. Increasing Returns in Drug
Discovery
Harnessing the Power of CellsTM
Executive Overview

2. Focus:
Provide pre-clinical development tools and methods to enable successful
outcomes in early phase drug discovery. Failure is success when
determined early.*
*90% of lead candidates identified by current in vitro systems fail to become drugs
Value Summary:
 Physiologically relevant human stem-derived terminally differentiated
cells, cellular systems and primary cell lines
 Better in vitro screening of targets and molecules =
 Reduced animal model use
 Shorten development timeline
 Lower downstream costs
*Expanding hN2 Primary Human Neurons stained with
our chicken polyclonal antibody to Vimentin and DAPI
(blue)
MSCGro™ Media vs Alternative
Executive Overview-V1-30-2013

3. Why Consider our Solutions
 Research proven solutions used by large Pharmas, Biotechs,
Academic and Government Labs. 2500+ customers
 Publications/Testimonials
 Lower per well costs-we can aggressively discount cells and media
 Customer success focused
 Expert technical support
 Detailed protocols and methods
 Quick replacements and reorders
 Large expert resource network
 Published expert input
 Non confidential; customer feedback and data sharing
through social media outlets and blogs
Executive Overview-V2-30-2013

4. Applications
High throughput and high content screening
 Compound Testing
 Toxicology Studies
 Discovery
Cell expansion, differentiation and migration
studies
In Vivo cell Imaging
Images: To demonstrate the capabilities of the NIR-FLIVO® 747 apoptosis Images: (A) UCB Derived hMSCs cultured using our low
tracer, adult wild-type Balb/c mice were either inoculated with HSV-1 virus, Serum MSCGro media and then differentiated using our
which is known to induce apoptosis in the brain, or given a sham treatment. Oetsogenic Differentiation Media.
Seven days after viral inoculation, the mice were injected intravenously with
either the NIR-FLIVO® 747apoptosis tracer (cat. KF17368), the NIR-FLIVO®
747 free dye (cat. KF17370, DyLight®747), or no reagent. Executive Overview-V3-03-2013

5. Cell Based Assays FITC Labeled
hChondrocytes
Tools Include:
• Growth-
Differentiation
Factors
• High- FITC Labeled 3-D Solutions
Performance hOsteoblasts
Media Human Mesenchymal
• Transfection Stem Cells-Green
Kits Fluorescent-Labeled
• Markers
• 3-D hDopamingergic
Fibers/ECMs Neurons Derived
using hGNDF
Migration Assays
Coming soon! Courtesy of Essen
SPIO-Labeled hN2 Human Neurons Biosciences
Cells for in-vivo (mixed) stained with
Imaging MAP-2 , Courtesy of
Dr. Gerry Shaw, UF
hNP1 Neural
Progenitors-100%
Confluency
Testimonial: got 10 million cells total after extraction from the tissue. At Day 4 they all developed long axons. Thank you
so much for the replacement." Dr. Lidia Gardner, University of Tennessee HSC.
Executive Overview-V3-03-2013

6. Example hNP1TM Neural Progenitors to Sensory Neurons: Xiufang Guo, Severo Spradling, Maria
Stancescu, Stephen Lambert, James J. Hickman. Derivation of sensory neurons and neural crest
stem cells from human neural progenitor hNP1. Biomaterials, In Press, Corrected Proof,Mar
2013.doi:10.1016/j.biomaterials.2013.02.061.
Images: Phase contrast images of the cultures before and after the sensory neuron induction. A) hNP1 culture before sensory
induction. B) hNP1 culture 10 days after sensory induction. C) hNP1 culture 30 days after sensory induction. Neuronal clusters and
axonal bundles, which resemble rat DRG cell cultures, were typically observed. D) For comparison, an image of a rat embryonic DRG
cell culture at 7 DIV is provided.
Executive Overview-V3-03-2013

7. Key Product Category Links:
 Cell Based Assay-Cells, Media and 3-D Solutions, stem cell potency/toxicity
 Antibodies-Markers-internally developed markers for neuroscience, immune
response, cancer, Autoimmune disease and stem cell research
 Apoptosis Research Reagents -includes: detection kits, antibodies and
proteins
 Proteins Recombinant and natural proteins-includes a wide selection of cell
growth factors.
 Transfection & Reagents-Gene Expression Analysis,
engineered cell lines for custom applications
Executive Overview-V2-30-2013

8. Competitive advantages
 Human Stem cell-derived: less animal studies, highly reproducible, cost-
effective, bulk cells/systems of in-vivo replicates as in-vitro, defined systems.
 Expertise in Stem Cell Differentiation: Substantial experience in differentiation,
trans-differentiation and characterization
 NSC & MSC-derived cell systems: Neurons, DA and mixed, 5-HT, ACh, NE, GABA-
nergic, etc. MSC-derived chondrocytes, osteoblasts and endothelial cells.
 IPSC-based cell-line generation platform: The classic four-gene method of
Grudin and Yamanaka, the 2012 Nobel Prize winners, can be replaced by over-
expression of Oct 3/4 only in adult stem cells & Vitro Biopharma has a
proprietary position (with licensing opportunities). IPSCs platform provides
capacity for any human cell lineage.
 Transfection Expertise: This allows us to provide custom engineered cell systems
for HTP screening.
 Cell labeling: Stem cell/derivative labeling by fluorescent, magnetic and
nanoparticle-based probes. Ideal for in-vivo imaging, HTP and marker analysis.
 Technical Support: Substantial technical support in all phases of projects.
Executive Overview-V2-30-2013

9.  Clear Understanding of where Neuromics/Vitro Biopharma
could have a positive impact.
 More intense in vitro screening of compounds and targets.
 Better candidates for downstream processes.
 Tools for in vivo assays
 Propose solutions based on this understanding
 Follow up, tweak and improve
Pete Shuster
CEO and Owner
Direct Phone: 612-801-1007
pshuster@neuromics.com
Executive Overview-V2-30-2013